Figure 1: Flowchart of the study
FIGURE 1
Figure 1: Flowchart of the study
Figure 2: Intragroup statistical comparison analysis of the Quality of Life (SF-36 somatic and mental health scores) of women on LARC and on SARC methods over the 24-month study with baseline values, after termination for unintended pregnancy. *Vs Baseline, p<0.001
Figure 3: Intergroup statistical comparison analysis of the Quality of Life (SF-36 somatic and mental health scores) of women on LARC and on SARC methods over the 24-month study, after termination for unintended pregnancy
Antisense Oligonucleotide (ASO) targeting TCTP (called TCTP-ASO) is associated with a carrier (1), facilitating its cellular delivery. Alternatively, Lipid-modified TCTP ASO (TCTP-LASO) can be self- assembled into nanomicelle (2) which can encapsulate with a DNA damage poisoner (3) and go through the cell without delivery-aid (4). Inside the cell, ASO and LASO and encapsulated drugs can be released (5). ASO and LASO hybrid to the specific sequence of TCTP pre-mRNAs or mRNAs (6), leading to downregulation of TCTP protein (7). In addition, other small molecules (such as Sertraline and Thioridazine) also can be used to decrease TCTP protein level (8). These TCTP inhibitors (including TCTP-ASO and small molecules) can be used in parallel with DNA damage caused therapies (Irradiation, chemo drugs). On the other hand, the encapsulated DNA damage chemo-drugs released from the nanomicelles can induce DNA damages (9), which subsequently triggers DNA damage responses (DDRs) (10). TCTP downregulation interrupts DDRs (11), thereby blocking cell cycle arrest and DNA repair, promoting Apoptosis/Senescence, leading to decrease in possibilities of mutagenesis/cancer progression and treatment resistances (12)
Figure 4: Strategies of combinatorial treatment with TCTP inhibitors and DNA poisoners
Tables at a glance
Figures at a glance